RT Journal Article
SR Electronic
T1 Changes in local immune status in tonsillopharyngitis under pathogenic therapy with the BNO 1030 extract: a randomized, comparative, parallel-group, single-center study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.28.23293249
DO 10.1101/2023.07.28.23293249
A1 Savlevich, Elena L.
A1 Kozlov, Vladimir S.
A1 Gaponov, Andrey M.
A1 Gerasimov, Andrey N.
A1 Markus, Petr V.
A1 Yakushenko, Elena V.
A1 Doroshchenko, Natalia E.
A1 Kozlov, Ivan G.
YR 2023
UL http://medrxiv.org/content/early/2023/08/08/2023.07.28.23293249.abstract
AB Aim of study The present study aimed to evaluate anti-inflammatory and immunomodulating properties of BNO 1030 (Tonsilgon® N) and its direct effect on the indicators of the local immunity of oropharyngeal mucosa in patients with acute tonsillopharyngitis (TP) or exacerbation of chronic TP without evident systemic inflammatory syndrome.Materials and methods A total of 60 adult patients with acute TP or exacerbation of chronic TP without severe systemic inflammatory syndrome were randomly divided into 2 groups: Group 1 L 30 patients took BNO 1030 (Tonsilgon® N), Group 2 L 30 patients took sage tablets according to the summary of product characteristics during 7 days. During 3 visits (day 1, day 3, day 7) symptoms and oropharyngeal mucosa condition were evaluated using a 10-point visual analogue scale (VAS). Local immunity parameters of oropharyngeal mucosa (cytokines: IL-1β, IL-6, IL-8, IL-10, IL-17, TNF-α, and lysozyme, lactoferrin, sIgA) were determined by ELISA and by real time polymerase chain reaction.Results Reduction of the main symptoms was significantly faster under BNO 1030 therapy than under sage therapy. In BNO 1030 group reduction of clinical symptoms correlated with the onset of action and the local immunological parameters. During BNO 1030 treatment IL-1β, IL-6, and IL-8 mRNA levels decreased below the levels in healthy controls, while, the immune factors lysozyme, lactoferrin and sIgA increased. Therapy with sage tablets did not affect local immunity parameters.Conclusion Both treatment regimens resulted in elimination of clinical signs and mucosal pharyngeal barrier regeneration. In contrast to the sage tablets, BNO 1030 can also affect local mucosal immunity via regulating the balance of pro- and anti-inflammatory factors.This study can answer the question regarding influence on main local immunity parameters of subjects with tonsillitisThe one of main task of this study is to evaluate what local immune parameters of oral cavity are most changeableTonsilgon N usage is not decrease main local immunity parameters such as IL-1β, IL-8, lysozyme and lactoferrinThis study evaluated the functional condition of mucosal immunity of oral cavity in subjects with tonsillopharingitisCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN registry #ISRCTN80067058, https://doi.org/10.1186/ISRCTN80067058Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee at Federal State Budgetary Institution Policlinic #3 (31 Grokholsky lane, Moscow 129090; +7 495 9826571; anikin_gs@pudb.ruI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.BNO 1030Tonsilgon N: Herbal medicinal product containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herbCDcluster of differentiationENTear nose throatFGBUFederal State Budgetary InstitutionIFNinterferonILinterleukinMCPmonocyte chemotactic proteinMDCKMadin-Darby canine kidney cellsMemedianmRNAmessenger ribonucleic acidNK cellsnatural killer cellsNODnucleotide-binding oligomerization domain-like receptorsPAMPspathogen-associated molecular patternsPCRpolymerase chain reactionRANTESregulated upon activation, normal T cell expressed and secretedRNAribonucleic acidRT-PCRreal time polymerase chain reactionRQrelative quantitySDstandard deviationsIgAsecretory immunoglobuline ASmPCSummary of product characteristicsTLRsToll-like receptorsTNFtumor necrosis factorTPtonsillopharyngitisVASvisual analogue scale